Taken together, these data indicated that the sustained exposure to IGFBP-1 results in increased EGFR signaling in breast cancer cells and this transition to EGF sensitivity is similar to the transition that occurs during development of tamoxifen resistance in breast cancer cells. The gene discussed is IGFBP1; the disease is breast cancer.